Lia Gore
University of Colorado Cancer Center
Aurora
Colorado
USA
Name/email consistency: high
- A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Gore, L., Rothenberg, M.L., O'Bryant, C.L., Schultz, M.K., Sandler, A.B., Coffin, D., McCoy, C., Schott, A., Scholz, C., Eckhardt, S.G. Clin. Cancer Res. (2008)
- Forodesine treatment and post-transplant graft-versus-host disease in two patients with acute leukemia: facilitation of graft-versus-leukemia effect? Gore, L., Stelljes, M., Stelljes, M., Quinones, R. Semin. Oncol. (2007)
- A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors. Gore, L., Holden, S.N., Cohen, R.B., Morrow, M., Pierson, A.S., O'Bryant, C.L., Persky, M., Gustafson, D., Mikule, C., Zhang, S., Palmer, P.A., Eckhardt, S.G. Ann. Oncol. (2006)
- Long-term survival after intralesional resection and multi-modal therapy of thoracic spine osteosarcoma. Gore, L., Greffe, B.S., Rothenberg, S.S., Erickson, M., Schreiber, D.P., Handler, M.H. Med. Pediatr. Oncol. (2003)